Gene · 2568
GABRP: gamma-aminobutyric acid type A receptor subunit pi
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. GABRP: gamma-aminobutyric acid type A receptor subunit pi. Genes, record 2568. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/2568
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| O00591 | Gamma-aminobutyric acid receptor subunit pi | 440 | 2 | Ensembl, GeneID, HGNC |
Source UniProt
Patents57
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 47271 | O00591 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 47273 | O00591 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 2458 | O00591 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 5706 | O00591 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 5707 | O00591 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 1666 | O00591 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 6443 | O00591 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 1666 | O00591 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 6443 | O00591 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 2458 | O00591 | Espacenet |
1 to 10 of 57
See all 57 patentsDrugs76
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ABP-700 | CHEMBL4297255 | GABA-A receptor; anion channel agonist | AGONIST | ChEMBL |
| ACAMPROSATE | CHEMBL1201293 | GABA-A receptor; anion channel positive modulator | POSITIVE MODULATOR | ChEMBL |
| ACAMPROSATE CALCIUM | CHEMBL2068724 | GABA-A receptor; anion channel positive modulator | POSITIVE MODULATOR | ChEMBL |
| ADIPIPLON | CHEMBL2103791 | GABA-A receptor; anion channel partial agonist | PARTIAL AGONIST | ChEMBL |
| ALPRAZOLAM | CHEMBL661 | GABA-A receptor; anion channel positive allosteric modulator | POSITIVE ALLOSTERIC MODULATOR | ChEMBL |
| BREXANOLONE | CHEMBL207538 | GABA-A receptor; anion channel positive allosteric modulator | POSITIVE ALLOSTERIC MODULATOR | ChEMBL |
| BUTABARBITAL | CHEMBL449 | GABA-A receptor; anion channel positive allosteric modulator | POSITIVE ALLOSTERIC MODULATOR | ChEMBL |
| BUTABARBITAL SODIUM | CHEMBL1200982 | GABA-A receptor; anion channel positive allosteric modulator | POSITIVE ALLOSTERIC MODULATOR | ChEMBL |
| BUTALBITAL | CHEMBL454 | GABA-A receptor; anion channel positive allosteric modulator | POSITIVE ALLOSTERIC MODULATOR | ChEMBL |
| CENOBAMATE | CHEMBL3989949 | GABA-A receptor; anion channel positive allosteric modulator | POSITIVE ALLOSTERIC MODULATOR | ChEMBL |
1 to 10 of 76
See all 76 drugsTrials1,164
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07602400 | SEVOFLURANE | ClinicalTrials.gov | ||
| NCT07602400 | PROPOFOL | ClinicalTrials.gov | ||
| NCT07588750 | TOPIRAMATE | ClinicalTrials.gov | ||
| NCT07584902 | CIPEPOFOL | ClinicalTrials.gov | ||
| NCT07584902 | PROPOFOL | ClinicalTrials.gov | ||
| NCT07569198 | MIDAZOLAM | PHASE2 | ClinicalTrials.gov | |
| NCT07568938 | DESFLURANE | ClinicalTrials.gov | ||
| NCT07560878 | LORAZEPAM | EARLY_PHASE1 | ClinicalTrials.gov | |
| NCT07532733 | PROPOFOL | ClinicalTrials.gov | ||
| NCT07513870 | SEVOFLURANE | ClinicalTrials.gov |
1 to 10 of 1,164
See all 1,164 trialsNIH grants341
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | GABRP papers | Newest fiscal year |
|---|---|---|---|
| UL1TR001863 | Yale Clinical and Translational Science Award | 3 | 2025 |
| P30CA006516 | Dana-Farber/Harvard Cancer Center | 2 | 2025 |
| P30CA043703 | Case Comprehensive Cancer Center Support Grant | 2 | 2025 |
| P30CA118100 | University of New Mexico Cancer Center Support Grant | 2 | 2025 |
| R01DE023222 | Mutations and Target Genes in Adenoid Cystic Carcinoma | 2 | 2025 |
| R01HD094937 | Modeling Normal and Abnormal Trophoblasts | 2 | 2025 |
| T32GM145304 | Cellular Biotechnology Training Program (CBTP) - Years 31-35 | 2 | 2025 |
| ZIAAA000301 | Integrative genetics of behavior with high throughput technologies | 2 | 2025 |
| K12DA000167 | Clinician Scientist Training Program (CSTP) | 1 | 2025 |
| K12GM106996 | IRACDA at UCLA | 1 | 2025 |
1 to 10 of 341Source NIH's project files
See all 341 nih grantsPapers396
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Identification and Functional Characteristics of NR5A1 Gene Variant in Patients with 46,XY Disorders of Sex Development. | Genes (Basel) | 2026 | 42792964 | PubTator, text mining | PubMed |
| Risk Factors and Biomarkers for Immune Checkpoint Inhibitor-mediated Hepatotoxicity: Emerging Insights and Future Perspectives. | J Clin Transl Hepatol | 2026 | 41810106 | PubTator, text mining | PubMed |
| Essential tremor: Family-based sequencing suggests involvement of neuronal and metabolic pathways. | Parkinsonism Relat Disord | 2026 | 41762786 | PubTator, text mining | PubMed |
| Targeted biologics for TNBC: Advances in nanobodies, antibodies, peptides, and aptamers. | Mol Ther Oncol | 2026 | 41716468 | PubTator, text mining | PubMed |
| RNAseq-based meta-analyses revealed tumor suppressor-inducer fusion events in liver, oral, and ovarian cancer in the Indian population: a cancer cell surviving mechanism. | Nucleosides Nucleotides Nucleic Acids | 2026 | 41661231 | PubTator, text mining | PubMed |
| The influence of neuro-tumor interactions on tumorigenesis and therapeutic response. | Exp Hematol Oncol | 2026 | 41645346 | PubTator, text mining | PubMed |
| Single-Cell RNA Sequencing and Bulk RNA Sequencing Revealed the Interplay Between Intratumoral Heterogeneity and the Tumor Microenvironment in Breast Cancer. | Cancer Med | 2026 | 41635010 | PubTator, text mining | PubMed |
| Shedding light on the function of autophagy in complicated pregnancies. | Cell Death Dis | 2026 | 41507150 | PubTator, text mining | PubMed |
| Children with Autism Spectrum Disorder and Chronic Gastrointestinal Symptoms Have Alterations in Intestinal Neurotransmitter Pathways. | Dig Dis Sci | 2026 | 41504861 | PubTator, text mining | PubMed |
| Multi-omics unravel heterogeneity of glucose metabolism reprogramming in gastric cancer. | Clin Exp Med | 2025 | 41249595 | PubTator, text mining | PubMed |
1 to 10 of 396
See all 396 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/2568
GET https://conductscience.org/api/genes/v1/2568/patents?page=2